Posted by Polymeric nanobubbles were prepared by using polybutlycyanoacrylate. The incorporation of near-infrared dye (IR780) resulted in a multimodal contrast NB, which allows in vitro and in vivo visualization on both ultrasound and optical imaging. Furthermore, these NBs can be triggered by ultrasonic bursts to release their dye/drug payload. The safety profile of the NBs, post-incorporation of CD (CDNBs), demonstrated excellent biocompatibility in vitro using cell culture and in human blood. Cellular uptake of CP increased by 2.4x when using CPNBs compared to free CD (p<0.00001). In vivo biodistribution demonstrated that the NBs circulate in blood plasma for 48 hours, with a peak at 1-hour post-injection. In a mouse model of atherosclerosis, ApoE-/- mice on high-fat diet, we intravenously injected CDNBs, free CD or NBs only fortnightly for 8 weeks. The passive accumulation of CDNPs in the atherosclerotic lesions, resulted in the release of CD and the reduction of total plaque area in the entire aorta. These CDNBs treated mice also have a reduced cholesterol level in their plasma.
X Wang, S Mehta, V Bongcaron, T Nguyen, Y Jirwankar, A Maluenda, A P G Walsh, J Palasubramaniam, M Hulett, R Srivastava, A Bobik, K Peter, Cyclodextrin-loaded nanobubbles reduce cholesterol and atherosclerosis in vivo, European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.3257, https://doi.org/10.1093/eurheartj/ehad655.3257